siponimod and Disease-Resistance

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system (CNS) with heterogeneous pathophysiology. In its progressive course oligodendrocyte and neuroaxonal damage is sustained by compartmentalized inflammation due to glial dysregulation. Siponimod (BAF312), a modulator of two sphingosine-1-phosphate (S1P) receptors (S1P1 and S1P5) is the first oral treatment specifically approved for active secondary progressive MS. To address potential direct effects of BAF312 on glial function and glia-neuron interaction, we set up a series of

Topics: Astrocytes; Azetidines; Benzyl Compounds; Cell Differentiation; Cells, Cultured; Disease Resistance; Down-Regulation; Excitatory Amino Acid Transporter 2; Fibroblasts; Humans; Multiple Sclerosis; Neurodegenerative Diseases; NF-E2-Related Factor 2; NF-kappa B; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators